Brief: Qlife Provides Update On Operational Progress In China
Jan 7 (Reuters) - Qlife Holding AB QLIFE.ST :
* PROVIDES UPDATE ON OPERATIONAL PROGRESS IN CHINA
* STRATEGIC PARTNER IN CHINA, HIPRO BIOTECHNOLOGY, HAS
SUCCESSFULLY COMPLETED INITIAL CLINICAL STUDY WITH EXCELLENT
RESULTS
* FINAL PHASE OF CLINICAL STUDY IS EXPECTED TO CONCLUDE IN
FIRST
HALF OF 2025
Source text: ID:nWkr28zxmB
Further company coverage: QLIFE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Qlife Holding AB
See all newsAdvisory: Alerts on Qlife's agreement with global pharma company withdrawn
Brief: Qlife Holding Enters Feasibility Deal With Pharma Co For Egoo Health Biomarker
Brief: Qlife Holding Q1 EBITDA Loss SEK 5.5 Mln
Sweden's Qlife Q1 revenue drops, losses widen slightly
Brief: Qlife Holding Q4 EBITDA At SEK -1.6 Million